RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Idebenone Delays Respiratory Decline in Duchenne Muscular Dystrophy
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 6
OP 7
DO 10.1177/1559897715588490
UL http://mdc.sagepub.com/content/15/9/6.abstract
AB The randomized phase 3 DELOS trial was designed to evaluate idebenone, a synthetic quinone compound, in Duchenne muscular dystrophy. The data showed that idebenone was safe and well tolerated, and it significantly reduced loss of respiratory function in patients aged 10 to 18 years.